A recent case series (9 patients) and an US Food and Drug Administration advisory (73 cases, 44 type 2 diabetes [T2D] cases, 15 type 1 diabetes [T1D] cases) have described euglycemic DKA and ketoacidosis with SGLT2 inhibitors.11,12 A phase II double-blinded study of canagliflozin added to insulin therapy in T1D diabetics found that canagliflozin 100 mg and 300 mg was associated with an increased risk of DKA requiring hospitalization as compared with placebo (4.3%, 6%, and 0%, respectively).13 Here, INS is linked to type 2 diabetes mellitus.